Want to see IN:SMSPHARMA full AI Analyst Report?
SMSPHARMA Stock Chart & Stats
₹380.80
₹10.80(2.83%)
At close: 4:00 PM EDT
₹380.80
₹10.80(2.83%)
Day’s Range― - ―
52-Week Range₹230.75 - ₹446.50
Previous CloseN/A
Volume99.05K
Average Volume (3M)105.50K
Market Cap
₹33.28B
Enterprise Value₹38.28K
Total Cash (Recent Filing)₹460.75M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)33.1
Beta1.48
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)11.24
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)4.36
Price to Sales (P/S)3.87
P/FCF Ratio-37.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings RecoveryRecent growth and a return to solid profitability indicate improved operating performance after the FY2023 loss. Sustained API demand and earnings recovery could support reinvestment and strengthen the company’s earnings base over the next several quarters.
Debt Reduction And Stronger Equity BaseLower debt and higher equity improve financial resilience, reduce balance-sheet pressure and provide greater flexibility to fund manufacturing needs. This strengthens the company’s ability to manage industry cycles and absorb operational volatility.
Essential API Manufacturing FocusAPIs are essential inputs for finished medicines, giving the business a role within established pharmaceutical supply chains. Exposure to both domestic and international formulation markets supports a durable operating model beyond a single end market.
Bears Say
Weak Cash ConversionLow conversion of accounting earnings into operating cash raises questions about working-capital requirements and earnings quality. If this persists, internally generated funds may be insufficient to support capacity, maintenance and other business needs.
Recurring Negative Free Cash FlowRepeated negative free cash flow indicates that capital expenditure and working-capital demands are absorbing more cash than operations generate. This can constrain deleveraging, limit shareholder distributions and increase reliance on external funding.
Volatile Margins And Earnings PowerSharp margin variation and a recent loss year suggest exposure to product mix, input costs and pharmaceutical-cycle conditions. Uneven profitability makes it harder to assess sustainable returns and increases the risk of renewed earnings weakness.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹230.75 and its highest was ₹446.50 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹33.28B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Nov 06, 2026 which is in 66 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on Jul 31, 2026. The company reported ₹2.233 earnings per share for the quarter.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.11%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹2.233 in its last earnings report. Following the earnings report the stock price went up 0.12%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of APIs targeting various therapeutic categories, including anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral applications. Furthermore, SMS Pharmaceuticals engages in contract research activities and exports its products globally.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Senores Pharmaceuticals Ltd.
―